Concurrent Liposomal Cisplatin (Lipoplatin), 5-Fluorouracil and Radiotherapy for the Treatment of Locally Advanced Gastric Cancer: A Phase I/II Study

The status of platinum anticancer drugs in the clinic and in clinical trials

“…234 Twelve patients were treated with Lipoplatin at a dose of 120 mg m -2 week -1 , 5-FU at 400 mg m -2 week -1 (day 1), and radiotherapy was given through 3.5-Gy fractions on days 2, 3, and 4. 234 Minimal nephrotoxicity and neutropenia were reported.…”

“…234 Twelve patients were treated with Lipoplatin at a dose of 120 mg m -2 week -1 , 5-FU at 400 mg m -2 week -1 (day 1), and radiotherapy was given through 3.5-Gy fractions on days 2, 3, and 4. 234 Minimal nephrotoxicity and neutropenia were reported. 234 Response rates reached 80% tumour disappearance in patients receiving five cycles, supporting further studies of Lipoplatin in adjuvant postoperative or preoperative radio-chemotherapy regimes for the treatment of gastric cancer.…”

Two consecutive days of treatment with liposomal cisplatin in non-small cell lung cancer

“…It has also been administered on days 1 and 8 and repeated on the 21st day (24)(25)(26)(27)(28). To determine the toxicity and effectiveness in the present study, the agent was administered for 2 consecutive days every 2 weeks.…”

Experimental Therapies in Breast Cancer

“…Several decades of research has been invested to understanding how liposomal or vesicular drug delivery can be enacted to deploy their drug payloads (Gradishar et al 2005;Cho et al 2008). As purported by Koukourakis et al (2010) use of liposomes can result in highly selective localization of drugs systems within tumors, which can serve as an effective modality of treatment when chemotherapy is combined with radiotherapy (Patel et al 1984). This concept has particular importance for radiation oncology as the radiation exposure to normal tissue within the radiation field can be reduced while maintaining high intratumor concentrations of a chemo agent (Patel et al 1984).…”